|Product Name||CAD031 powder|
|Synonym||CAD-031; CAD 031; CAD-31; CAD 31; CAD31;|
|Chemical Name||Acetic acid, 2,2,2-trifluoro-, (2E)-1-(2,4-dimethylphenyl)-2-[[3-(trifluoromethoxy)phenyl]methylene]hydrazide|
|Boiling point||386.8±52.0 °C(Predicted)|
|Solubility||Soluble in DMSO|
|Storage Temperature||-20°C 12 Months; 4°C 6 Months|
|Application||As a drug candidate for Alzheimer’s disease (AD)|
What is CAD031 powder?
CAD031, also known as CAD31, is a new type of brain penetrant, a J147 derivative and a drug candidate for Alzheimer’s disease (AD). It has higher neurogenic activity in human neural precursor cells (NPC) than J147; and has effective neuroprotective properties in six different neuronal cell assays, which can mimic the toxicity observed in the old brain . In addition, CAD-31 is permeable and may be very safe. It has important effects on synapse formation and AD energy metabolism pathway. CAD-31 also shows positive effects in preventing certain toxic events in neurodegenerative diseases related to old age.
The experiment found that CAD031 also stimulated the division of NPC in the subventricular area of old APPswe/PS1E9 mice; rescued primary cortical neurons from oxidation, and effectively reduced oxidative stress with an EC50 of 20 nM; in an in vitro ischemia model When the EC50 is 47 nM, it can also prevent the loss of energy metabolism, leading to neuronal cell death; targeting fatty acid metabolism and inflammation, showing therapeutic efficacy on cognitive and physiological parameters in AD mouse models.
How does CAD031 powder work?
Studies showed that CAD031 targets acetyl-CoA and fatty acid metabolism via the AMPK/ACC1 pathway. Importantly, CAD031 extended the median lifespan of SAMP8 mice by about 30%. These data show that specific alterations in mitochondrial composition and metabolism highly correlate with aging, supporting the use AD drug candidates that limit physiological aging in the brain.
CAD031 powder benefits
sCAD031 is an Alzheimer’s disease (AD) drug candidate for AD;
sCAD031 is broadly neuroprotective
sCAD031 has an excellent pharmacological and safety profile
sCAD031 reverses some aspects of cognitive dysfunction in old transgenic AD mice
sCAD031 can reduce inflammation, target lipid metabolism, and is a marker for increasing neurogenesis and synapses;
 Antonio Currais; Ling Huang; Michael Petrascheck; Pamela Maher; David Schubert . (2020). A chemical biology approach to identifying molecular pathways associated with aging. GeroScience, PMID: 32705410.
 Daugherty D, et al. Alzheimers Res Ther. 2017 Jul 14;9(1):50.
 Chen Q, Prior M, Dargusch R, Roberts A, Riek R, Eichmann C, et al. A novel neurotrophic drug for cognitive enhancement and Alzheimer’s disease. PLoS One. 2011;6(12):e27865. doi: 10.1371/journal.pone.0027865. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
 Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer’s disease mice. Alzheimers Res Ther. 2013;5(3):25. doi: 10.1186/alzrt179. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
 Prior M, Goldberg J, Chiruta C, Farrokhi C, Kopynets M, Roberts AJ, et al. Selecting for neurogenic potential as an alternative for Alzheimer’s disease drug discovery. Alzheimers Dement. 2016;12(6):678– doi: 10.1016/j.jalz.2016.03.016. [PMC free article] [PubMed] [CrossRef] [Google Scholar]